Characteristics and Cardiovascular and Mortality Outcomes in Patients With Type 2 Diabetes Mellitus Initiating Treatment With Sodium-glucose Co-transporter-2 Inhibitors (SGLT-2i) and Other Glucose Lowering Drugs

Trial Profile

Characteristics and Cardiovascular and Mortality Outcomes in Patients With Type 2 Diabetes Mellitus Initiating Treatment With Sodium-glucose Co-transporter-2 Inhibitors (SGLT-2i) and Other Glucose Lowering Drugs

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms CVD-REAL
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Dec 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2017.
    • 31 Dec 2017 Planned primary completion date changed from 1 Jun 2017 to 31 Dec 2017.
    • 15 Sep 2017 Results (n= 77,074) assessing association between hospitalisations and the use of dapagliflozin or DPP4 inhibitors, presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top